Posters
Glomerular Diseases: Clinical, Outcomes, and Therapeutics Research - IgAN
October 22, 2026 | 10:00 AM - 12:00 PM
Location: Exhibit Hall A, Convention Center
Session Description
Poster Session
Posters
Evaluating Gd-IgA1 for Early Detection and Monitoring of IgAN
Sparsentan (SPAR) vs. Irbesartan (IRB) in Patients (Pts) with FSGS Without Nephrotic Syndrome (NS) in the Phase 3 DUPLEX Trial
Patients with Newly Diagnosed IgAN Demonstrated Stable eGFR with First-Line Sparsentan (SPAR) over Two Years in the SPARTAN Final Analysis
IgA-C3 Complex Is Associated with Disease Severity and Proteinuria Remission in IgAN
Comparative Efficacy and Safety of IgAN Treatments: A Bayesian Network Meta-Analysis
Real-World Nephroprotective Effects of Dapagliflozin in IgAN: A Single-Center Experience
Efficacy of Nefecon in the Treatment of IgAN Complicated by Hepatitis B Virus Infection: A Single-Center Retrospective Study
Trajectory-Based Clustering of eGFR and Proteinuria Responses to Nefecon in IgAN: Identification of Distinct Clinical Phenotypes and Personalized Treatment Strategies
Real-World Multicenter Evidence on Nefecon for Attenuating Proteinuria and Kidney Function Decline in IgAN
Early Real-World Outcomes Among Patients (Pts) with IgAN Receiving Iptacopan: Analysis of the APPRISE-IgAN Data Platform
Urinary Activin A as a Prognostic Biomarker in IgAN
Increase in Serum Galactose-Deficient IgA1 Levels Measured by New Lectin Enzyme-Linked Immunosorbent Assay (ELISA) Predicts Progression to Kidney Failure in Adults with IgAN
Proteinuria and Kidney Outcomes in IgA Nephritis and IgA Nephritis with Vasculitis in Children and Adults in North America
Serum Galactose-Deficient IgA1 Levels in IgAN and Other Glomerular Diseases
Slowing of Kidney Function Decline to Physiological Rates with Nefecon in Patients with IgAN: A NefIgArd Subanalysis
Damage Accumulation over Time in an IgAN Cohort with Serial Kidney Biopsies
Real-World Use of Iptacopan in IgAN: A Retrospective Longitudinal Study in a Single Center
Sparsentan (SPAR) Safety Data from an Early Access Program (EAP) in IgAN
Efficacy and Safety of Nefecon in the Treatment of IgAN: A Multicenter Real-World Retrospective Study
Serum A Proliferation-Inducing Ligand Levels Are Associated with Proteinuria in Children and Adolescents with IgA Vasculitis Nephritis
Evidence of a Rapid and Localized Anti-Inflammatory Effect of Ravulizumab in IgAN: Prespecified Biomarker Analysis of the I CAN Phase 3 Trial
Longitudinal Proteinuria Change and eGFR Trajectory During Nefecon Therapy in Chinese Patients with IgAN: A Nine-Month Real-World Study
Patient Perceptions of Injectable Therapies Among Adults with IgAN: A Qualitative Study
Initial Treatment Practices for IgAN in Japan: A Descriptive Study Based on Health Checkup Findings Using Claims Database
Complement Inhibition in IgAN: A Systematic Review and Meta-Analysis of Clinical Trials
IgAN Treatment Patterns in 2026: Real-World Insights from 2,100 Patient Charts Across the United States, the Five Major European Markets (EU5), and China
C3 Hypocomplementemia at Diagnosis of IgAN Is Associated with a More Severe Clinical and Histopathological Phenotype
Contributions of IgAN to Kidney Failure: Global Trends from DOPPS
Finerenone as a Nephroprotective Agent in IgAN: A Prospective Six-Month Pilot Study
Nefecon Plus Systemic Telitacicept for IgAN: Early Proteinuria Improvement in a Propensity Score-Matched Cohort
Six-Month Proteinuria Reduction as a Robust Predictor of Five-Year Kidney Outcomes in IgAN
Efficacy and Safety of Iptacopan in East Asian Patients with IgAN: Final 24-Month Results from the Phase 3 APPLAUSE-IgAN Trial
Examining the Relationship Between Baseline Microscopic Hematuria and Immunosuppression Therapy in IgAN
Significance of Evaluating Glomerular Gd-IgA1 Deposition to Assess Disease Activity
Kidney Protection with Targeted-Release Budesonide (Nefecon) in IgAN Across Baseline Proteinuria Levels and Variable Proteinuria Response: A Real-World Study
Validation of the Klinrisk Machine Learning Model in Patients with IgAN
Dose-Dependent Efficacy and Safety of Atacicept in Patients with IgAN: A GRADE-Assessed Systematic Review and Meta-Analysis
Efficacy of Nefecon and Alteration of Plasma Gd-IgA1 and Poly-IgA Complexes in IgAN in China: Real-World Clinical Practice
Hemoglobinuria as a Biomarker of Inflammation in IgAN: Concordance with the Oxford Mesangial Hypercellularity, Endocapillary Hypercellularity, Segmental Sclerosis, Tubular Atrophy, and Crescent Formation (MEST-C) Score: A Multicenter Cohort Study
Treatment Patterns and Outcomes in IgAN: An Artificial Intelligence (AI)-Enabled Analysis of 480 Patients at a Large Community Practice
BRIDGE-IgAN: A Multicenter Retrospective Cohort Study of Health Outcomes Disparities in IgAN Across Diverse US Populations
A Proliferation-Inducing Ligand (APRIL), B-Cell-Activating Factor (BAFF), and Urinary CD163 Are Associated with Composite Kidney Outcomes Across Diverse Glomerular Disease Phenotypes
BRIDGE-GN: Development of an Integrated Real-World Clinical and Translational Research Ecosystem for Glomerular Diseases
Early Real-World Biomarker Trajectories After Sibeprenlimab Initiation in Patients with IgAN: A Multicenter Observational Cohort Study
Predictors of Response and Tolerability of Sparsentan in a Real-World IgAN Cohort
Early Real-World Experience with Sibeprenlimab in IgAN
Multicenter Diagnostic Evaluation of a Novel Gd-IgA1 Chemiluminescent Immunoassay (CLIA) for Primary IgAN
Efficacy and Safety of Nefecon in CKD Stage 3-4 IgAN: A Retrospective Real-World Study
Early Initiation of Targeted-Release Budesonide in IgAN with Low Baseline Proteinuria: A Real-World Analysis of Kidney Function Changes
Nefecon for IgAN with Lower Baseline Proteinuria: Significant Urine Protein-Creatinine Ratio (UPCR) Reduction and Preserved eGFR in Real-World Practice
Psoriasis-Associated IgAN: Clinicopathological Findings from a Matched Case-Control Study and Preliminary Experience with IL-17 Inhibitor (IL-17i) plus Telitacicept Therapy
Urinary V-Set Ig Domain-Containing Protein 4 (VSIG4) in IgAN: Correlation with Clinicopathological Features and Predictive Significance for Kidney Prognosis
Urinary N-Glycans Predict Long-Term Kidney Outcomes in IgAN
Treatment of IgAN According to Kidney Lesions: A Randomized Controlled Trial (TIGER Study)
Circulating Secretory IgA is a Potent Prognostic Biomarker of IgAN
Early Initiation Benefits of Nefecon in IgAN: A Real-World Study
Real-World Effectiveness, Safety, and Response Heterogeneity of Targeted-Release Formulation of Budesonide in Adults with IgAN
Persistent Hematuria at Nine Months Predicts Subsequent Proteinuria at 18 Months and Both Urinary Abnormalities Relate to Poor Prognosis in IgAN
Changes in Clinical and Biopsy Characteristics of Patients Diagnosed with IgAN over 12 Years: A Single-Center Study